A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics

Trial Profile

A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs SYNB 1020 (Primary)
  • Indications Hepatic encephalopathy; Inborn urea cycle disorders
  • Focus Adverse reactions; First in man
  • Sponsors Synlogic
  • Most Recent Events

    • 19 Jun 2017 According to a Synlogic media release, first patient has been dosed.
    • 01 Jun 2017 Status changed from planning to recruiting.
    • 24 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top